Tirzepatide (Mounjaro / Zepbound)
Tirzepatide is the first dual GIP/GLP-1 receptor agonist, FDA-approved as Mounjaro (T2D) and Zepbound (weight loss). SURMOUNT-1 showed 22.5% weight loss at 72 weeks. In a head-to-head trial against semaglutide (SURMOUNT-5), tirzepatide won by 47%: 20.2% vs 13.7% weight loss.
FormBlends Peptide Context
Reviewed May 14, 2026Tirzepatide peptide guide matters because the search behind it is usually practical. The reader is trying to understand GLP-1 treatment, peptide therapy, but the safer answer depends on context: diagnosis, medications, labs, dosing, access, price, and follow-up. This page should help narrow the next question before a licensed clinician or qualified provider weighs in.
- Confirm whether the page is discussing approved care, compounded access, off-label use, or research-only context.
- Check the date, evidence quality, safety limits, and whether newer clinical or regulatory updates may change the answer.
- Ask a licensed clinician how the information applies to your history, medications, labs, goals, and risk profile.
Clinical decision snapshot
Tirzepatide authority snapshot
Tirzepatide is evaluated by mechanism, evidence quality, regulatory status, practical access, and safety questions a licensed clinician would need to review before use.
Evidence signal
Strong human evidence
Regulatory reality
FDA approved for listed use cases
Safety screen
Nausea (up to 18%), Diarrhea (up to 17%), Decreased appetite should be reviewed in context.
This page currently connects to 12 source-backed evidence items through visible references or structured citation data.
Decision path
What is the supervised-review path for Tirzepatide?
Tirzepatide should be evaluated by evidence quality, safety status, source quality, dosing context, and whether the goal fits a legitimate clinical pathway. This page is a research and decision aid, not a self-prescribing guide.
- Peptide
- Tirzepatide
- Category
- Weight Loss
- Evidence
- Strong human evidence
- FDA status
- FDA approved
Step 1
Check evidence level
Tirzepatide has the strongest weight loss efficacy data of any approved medication. SURMOUNT-1 (n=2,539, NEJM 2022) showed 22.5% weight loss at 72 weeks. SURMOUNT-5 (n=751, NEJM 2025) demonstrated clear superiority over semaglutide in head-to-head comparison: 20.2% vs 13.7% at 72 weeks. SURPASS-2 confirmed superiority to semaglutide for both A1C and weight in T2D. The 3-year SURMOUNT-1 extension showed sustained weight loss and dramatic reduction in T2D progression.
Review evidenceStep 2
Screen safety context
Nausea (up to 18%), Diarrhea (up to 17%), Decreased appetite should be discussed in light of history, dose, and source.
Check side effectsStep 3
Confirm access route
If FormBlends offers access, review the product page and provider pathway before deciding.
Review product accessDual agonist decision hub
Tirzepatide is the high-efficacy option that needs careful fit checking
Tirzepatide is often the serious comparison point for patients who want the strongest available weight-loss signal from an approved incretin medication. Its dual GIP and GLP-1 activity makes it different from semaglutide, but the decision still comes down to eligibility, tolerability, supply route, dose escalation, and cost.
Decision question for Tirzepatide
Does the patient need top-end weight-loss potential enough to justify tirzepatide's cost and titration path?
Peptide evidence layer
Evidence read
The page should make the SURMOUNT evidence easy to interpret, including average weight loss, the number of patients reaching 20% loss, and how head-to-head comparisons differ from dose-for-dose marketing claims.
Safety watch
Provider review should address GI tolerance, gallbladder history, diabetes medications that raise hypoglycemia risk, pregnancy plans, dehydration risk, and whether the patient has already failed or plateaued on another incretin.
Conversion fit
The clean conversion path is not a hard sell. It is an intake that sorts new-start patients from switchers, plateau cases, and patients who may need slower titration.
Last updated: April 6, 2026
Typical Dosage
Start at 2.5 mg once weekly (initiation only, not maintenance). Titrate in 2.5 mg increments every 4+ weeks. Maintenance doses: 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg once weekly. Maximum: 15 mg/week.
Administration
Subcutaneous injection
Typical Cost
$150-300/month (compounded, limited availability); $299-1,086/month (brand)
FDA Status
FDA Approved
Half-Life
Approximately 5 days, enabling once-weekly subcutaneous dosing.
Onset of Action
Tmax 8-72 hours. Steady state at ~4 weeks. Appetite suppression typically noticeable within 1-2 weeks. Body composition changes measurable by 8-12 weeks.
Bioavailability
Approximately 80% via subcutaneous injection.
About Tirzepatide
Tirzepatide is a 39-amino-acid synthetic peptide and the first dual GIP/GLP-1 receptor agonist approved for clinical use. Its CAS number is 2023788-19-2, and its molecular weight is approximately 4,813.45 Da. Developed by Eli Lilly, it is marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. The molecule is engineered from native human GIP with a C20 fatty diacid (icosanedioic acid) conjugated at Lys20 for albumin binding and alpha-aminoisobutyric acid (Aib) substitutions at positions 2 and 13 for DPP-4 resistance. What makes tirzepatide's pharmacology distinctive is its imbalanced dual agonism: it has high affinity for the GIP receptor (comparable to native GIP) while its GLP-1 receptor affinity is approximately 18-20 times weaker than native GLP-1. This imbalance is intentional and produces effects that neither pathway achieves alone. The clinical data for tirzepatide is hard to argue with. SURMOUNT-1 (NEJM 2022, PMID: 35658024) enrolled 2,539 adults with obesity and showed dose-dependent weight loss of 16.0% (5 mg), 21.4% (10 mg), and 22.5% (15 mg) versus 2.4% on placebo at 72 weeks. At the 15 mg dose, 91% of participants lost at least 5% of body weight and 57% lost 20% or more. The head-to-head comparison everyone wanted came in SURMOUNT-5 (NEJM 2025, PMID: 40353578): 751 adults with obesity received either tirzepatide 15 mg or semaglutide 2.4 mg for 72 weeks. Tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide (p<0.001), a 47% relative advantage. Tirzepatide also had a lower GI discontinuation rate (2.7% vs 5.6%), suggesting better tolerability at maximum doses. SURMOUNT-4 (JAMA 2024, PMID: 38078870) demonstrated that continued treatment is necessary to maintain weight loss: after 36 weeks of open-label tirzepatide (producing ~21% weight loss), patients randomized to continue treatment lost an additional 5.5%, while those switched to placebo regained 14.0%. This underscores that tirzepatide, like all incretin agonists, requires ongoing treatment. The compounding landscape changed a lot in 2024-2025. Tirzepatide was removed from the FDA drug shortage list in October 2024, and enforcement grace periods for compounding ended by March 2025. As of April 2026, bulk compounding of tirzepatide copies is no longer broadly permitted. 503A pharmacies may compound for patients with documented medical necessity (such as verified allergy to an inactive ingredient in the branded product), but cost savings alone does not qualify. Lilly has pursued an aggressive pricing strategy to compete with compounders: Zepbound is available through LillyDirect at $299/month self-pay, with a Medicare pilot program capping patient cost at $50/month. Commercial insurance patients can pay as low as $25/month with Lilly's savings card. Side effects follow the GLP-1 class profile: nausea (up to 18%), diarrhea (up to 17%), decreased appetite, and vomiting. A boxed warning exists for thyroid C-cell tumors observed in rodents. Oral contraceptive absorption drops sharply (55-66% reduction in Cmax), requiring women to use non-oral contraception or barrier methods.
How Tirzepatide Works
Tirzepatide is a 39-amino-acid linear peptide based on native human GIP, conjugated to a C20 fatty diacid at Lys20 for albumin binding and Aib substitutions at positions 2 and 13 for DPP-4 resistance. It is an imbalanced dual agonist with high GIP receptor affinity (comparable to native GIP) and approximately 18-20x weaker GLP-1 receptor affinity than native GLP-1. GLP-1 activation provides appetite suppression, delayed gastric emptying, and glucose-dependent insulin secretion. GIP activation enhances fat metabolism, energy balance, and beta-cell function. The dual mechanism produces synergistic effects: improved insulin sensitivity, superior A1C reduction, and greater weight loss than GLP-1 agonism alone.
Receptor targets:
Benefits
- 22.5% weight loss at 72 weeks (SURMOUNT-1, 15 mg dose)
- 47% more weight loss than semaglutide head-to-head (SURMOUNT-5)
- 57% of participants on 15 mg achieved 20%+ weight loss
- Superior A1C reduction vs semaglutide in T2D (SURPASS-2)
- Improves both beta-cell function and insulin sensitivity
- Reduces cardiovascular risk markers (lipids, blood pressure, waist circumference)
- Lower GI discontinuation rate than semaglutide in head-to-head trial
- Sustained weight loss with 89.5% maintaining 80%+ of loss at 88 weeks (SURMOUNT-4)
What Does the Research Say?
Tirzepatide has the strongest weight loss efficacy data of any approved medication. SURMOUNT-1 (n=2,539, NEJM 2022) showed 22.5% weight loss at 72 weeks. SURMOUNT-5 (n=751, NEJM 2025) demonstrated clear superiority over semaglutide in head-to-head comparison: 20.2% vs 13.7% at 72 weeks. SURPASS-2 confirmed superiority to semaglutide for both A1C and weight in T2D. The 3-year SURMOUNT-1 extension showed sustained weight loss and dramatic reduction in T2D progression.
Tirzepatide Once Weekly for the Treatment of Obesity
New England Journal of Medicine, 2022 · DOI · PubMed
16-22.5% weight loss across doses vs 2.4% placebo at 72 weeks in 2,539 adults with obesity (SURMOUNT-1)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
New England Journal of Medicine, 2021 · DOI · PubMed
Tirzepatide superior to semaglutide 1 mg for both A1C reduction and weight loss at all doses in 1,879 T2D patients (SURPASS-2)
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Potential Side Effects
- Nausea (up to 18%)
- Diarrhea (up to 17%)
- Decreased appetite
- Vomiting
- Constipation
- Dyspepsia
- Injection site reactions
- Pancreatitis (risk comparable to other GLP-1 RAs)
- Gallbladder disease
- BOXED WARNING: Thyroid C-cell tumors in rodents (unknown human relevance)
Drug Interactions
| Compound | Interaction | Severity |
|---|---|---|
| Insulin | Increased hypoglycemia risk. Reduce insulin dose when initiating tirzepatide and monitor blood glucose. | major |
| Sulfonylureas | Increased hypoglycemia risk. Consider dose reduction. | major |
| Oral contraceptives | Reduced absorption due to delayed gastric emptying. Cmax of ethinyl estradiol/norgestimate reduced 55-66%. Switch to non-oral contraception or add barrier method for 4 weeks after initiation and each dose escalation. | major |
| Warfarin | Altered absorption possible. Monitor INR more frequently at initiation. | moderate |
Who Is Tirzepatide For?
Women
Equally effective across reproductive stages per SURMOUNT post-hoc analysis. Postmenopausal women on HRT lost 35% more weight than tirzepatide alone. Oral contraceptive efficacy reduced (Cmax of ethinyl estradiol reduced 55-66%). Switch to non-oral contraception or add barrier method. Discontinue 1-2 months before attempting conception.
Adults Over 50
No age-based dose adjustments needed. No significant differences in safety or efficacy in patients 65+ in clinical trials. Higher sensitivity to GI side effects may warrant slower titration. Monitor bone density as approximately 25% of total weight lost comes from lean mass. Cardiovascular benefit demonstrated in HFpEF trial.
Athletes
Not banned by WADA. Approximately 25% of weight lost comes from lean mass. Resistance training 2-5x/week and protein intake of 1.8-2.2 g/kg/day strongly recommended to preserve muscle mass.
Regulatory Status
FDA Approved
Yes
Approved for: Type 2 diabetes (Mounjaro), Chronic weight management (Zepbound)
Compounding Legal
Yes
2026 HHS Status
Compounding limited to documented medical necessity under 503A
Tirzepatide was removed from the FDA shortage list in October 2024. Bulk compounding of tirzepatide copies is no longer broadly permitted. 503A pharmacies may still compound for individual patients with documented medical necessity (e.g., verified allergy to inactive ingredient). Cost savings alone does not constitute medical necessity. Multiple court decisions have upheld FDA's position.
Last verified: 2026-04-06
Conditions Addressed
Get Tirzepatide from FormBlends
Pharmaceutical-grade tirzepatide with free physician consultation.
View Product DetailsFind a Tirzepatide Clinic Near You
Browse peptide therapy clinics in your area that offer tirzepatide treatments.
Find Peptide Clinics